Journey Medical Corp.
- DERM · Nasdaq
- Pharmaceutical Preparations
- Scottsdale, AZ
- 58 employees
- CIK 0001867066
Updated from SEC filings through
Top things to know
Executives
-
Claude Maraoui President & CEO 4, 2026-04-24 -
Joseph Benesch CFO 4, 2026-04-24 -
Ramsey Alloush Chief Operating Officer 4, 2026-04-24 - Lindsay A. Rosenwald, M.D. Executive Chairman 10-K, 2026-03-26
Journey Medical Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Scottsdale, AZ. It trades as DERM on Nasdaq. Revenue was $61.9M in the fiscal year ending December 31, 2025, +10.2% from the year before. It reported about 58 employees. Claude Maraoui is President & CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $61.9M 10-K, 2026-03-26 | $56.1M 10-K, 2026-03-26 | $79.2M 10-K, 2025-03-27 | $73.7M 10-K, 2024-03-29 | $63.1M 10-K, 2023-03-31 |
| Operating income | -$8.2M 10-K, 2026-03-26 | -$13.7M 10-K, 2026-03-26 | -$2.1M 10-K, 2025-03-27 | -$27.5M 10-K, 2024-03-29 | -$34.9M 10-K, 2023-03-31 |
| SG&A | $44.4M 10-K, 2026-03-26 | $40.2M 10-K, 2026-03-26 | $43.9M 10-K, 2025-03-27 | $59.5M 10-K, 2024-03-29 | $39.8M 10-K, 2023-03-31 |
| Net income | -$11.4M 10-K, 2026-03-26 | -$14.7M 10-K, 2026-03-26 | -$3.9M 10-K, 2025-03-27 | -$29.6M 10-K, 2024-03-29 | -$44.0M 10-K, 2023-03-31 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Claude Maraoui | President & CEO | 4, 2026-04-24 |
| Joseph Benesch | CFO | 4, 2026-04-24 |
| Ramsey Alloush Chief Operating Officer and General Counsel at Journey Medical (Nasdaq: DERM) | Chief Operating Officer | 4, 2026-04-24 |
| Lindsay A. Rosenwald, M.D. | Executive Chairman | 10-K, 2026-03-26 |
| Justin Smith | Director | 10-K, 2026-03-26 |
| Michael Pearce | Director | 10-K, 2026-03-26 |
| Miranda Toledano | Director | 10-K, 2026-03-26 |
| Neil Herskowitz | Director | 10-K, 2026-03-26 |
What Journey Medical Corp does
S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Public float | $84.7M (as of June 30, 2025) | 10-K, March 26, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 12, 2026 |
| Latest proxy statement | Meeting June 24, 2026 (filed April 30, 2026) | DEF 14A, April 30, 2026 |
| Auditor | Kpmg LLP (Short Hills, New Jersey) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-26
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-21
- Item 8.01 Other events
- 8-K filed 2026-03-25
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-26
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2025-08-28
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2025-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-07-14
- Item 8.01 Other events
Frequently asked questions about Journey Medical Corp
- What does Journey Medical Corp do?
- In its own words, from Item 1 of its 10-K: "S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”)."
- What is Journey Medical Corp's revenue?
- $61.9M for the fiscal year ending December 31, 2025, from its 10-K filed March 26, 2026.
- Is Journey Medical Corp profitable?
- Journey Medical Corp reported net income of -$11.4M for the fiscal year ending December 31, 2025.
- How many employees does Journey Medical Corp have?
- About 58 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Journey Medical Corp?
- Claude Maraoui, President & CEO, as named in a 4 filed April 24, 2026.
- Who is the CFO of Journey Medical Corp?
- Joseph Benesch, CFO, as named in a 4 filed April 24, 2026.
- Where is Journey Medical Corp headquartered?
- Scottsdale, AZ.
- What is Journey Medical Corp's stock ticker?
- DERM on Nasdaq.
- What industry is Journey Medical Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Journey Medical Corp's website?
- journeymedicalcorp.com.
- When does Journey Medical Corp report earnings next?
- November 12, 2026 at 16:30. Source: ir_events.
- Is Journey Medical Corp a public company?
- Yes. Journey Medical Corp files with the SEC under CIK 0001867066 and trades as DERM.
- Who audits Journey Medical Corp?
- Kpmg LLP, Short Hills, New Jersey, as named in its latest annual report (10-K).
- What is Journey Medical Corp's public float?
- $84.7M as of June 30, 2025, as reported on the cover of its 10-K filed March 26, 2026.
- How many business segments does Journey Medical Corp report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 12, 2026.
- When is Journey Medical Corp's annual shareholder meeting?
- June 24, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.